Topic: meningococcal group B
Pfizer’s vaccines business has for years centered on Prevnar 13, the world’s bestselling vaccine, and 2017 was no exception. But the company wants to change that—and for good reason.
The Pfizer men B shot grabs an approval-speeding designation just two months after GSK's Bexsero—Trumenba's archrival—got the same boost.
GlaxoSmithKline plans to explore MenB vaccine Bexsero's potential in preventing gonorrhea after a new study suggested plausible protection.
Bexsero has been helping drive revenue growth for GSK, but now, with an EU approval, Pfizer’s Trumenba is set to challenge it in that lucrative market.
With stellar vaccine sales for GlaxoSmithKline and Bexsero, GSK is building a $175 million plant in Germany to expand production of the meningococcal B shot.